Zydus Lifesciences Reports 20% Revenue Jump, 14% Profit Rise in Q2

12 Nov 2024 , 03:48 PM

Zydus Lifesciences Ltd., formerly known as Cadila Healthcare, reported strong second-quarter results with a 13.7% year-on-year increase in net profit, reaching ₹911 crore compared to ₹801 crore in the same period last year.

The company’s revenue for Q2 FY25 rose by 20% year-on-year to ₹5,237 crore, reflecting growth across its key segments. Investment in Research & Development (R&D) for the quarter amounted to ₹480 crore, representing 9.2% of the company’s total revenue. EBITDA for Q2 increased by 27.5% year-on-year to ₹1,461.4 crore, with EBITDA margins expanding by 170 basis points to 27.9%.

In the US formulations market, Zydus reported a 30% year-on-year revenue increase to ₹2,417 crore, accounting for 47% of the company’s consolidated revenue, despite a 22% sequential decline.

The company’s Active Pharmaceutical Ingredient (API) segment recorded revenues of ₹119 crore, showing a 15% year-on-year decrease and contributing 2% to total revenues. Capital expenditure (Capex) for Q2 was ₹302 crore, totaling ₹603 crore for the first half of FY25.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, attributed the robust performance to sustained growth momentum and the successful execution of its product pipeline in the US, alongside the strong performance of its India business.